spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Phillips-Medisize Enters Agreement with Global Pharmaceutical Company to Acquire Exclusive Ownership of Patents for an Innovative Mini-tablet Dispenser

Phillips-Medisize



HUDSON, WI – September 10, 2019 – Phillips-Medisize, a Molex company, announced today an agreement with a Global Pharmaceutical Company, where Phillips-Medisize acquired exclusive ownership of patents supporting an innovative mini-tablet dispenser to accommodate the varied and customized oral dispensing needs of patients.

“Through its unique working principle, the mini-tablet dispenser will be valuable in pediatrics, geriatrics and oncology where patients often require highly flexible oral dosing based on age, weight and other variables,” said Matt Jennings, CEO and President, Phillips-Medisize. “Furthermore, in smaller patient populations the option to flexibly count to combine incremental mini-tablet doses offers an advantage over preparing multiple fixed oral tablet dose strengths.”

The mini-tablet dispenser differentiates itself from most available systems that predominantly rely on volumetric measuring principles. With the assistance of this dispenser mounted on top of a standard tablet bottle, a patient or caregiver will be able to count and dispense mini-tablets in predetermined amounts from one to twenty tablets, and it supports tablets of approximately 2x2 mm to 2.3x2.3 mm dimensions. The mini-tablet dispenser enables the user to visually confirm the measured tablet count number before dispensing and is designed to minimize damage or crushing of the mini-tablets during dispensing.

Phillips-Medisize has begun industrialization preparations aiming to make the dispenser available to an array of pharmaceutical companies globally in early 2020.




About Phillips-Medisize

Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com

phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

New offices at leading science hub support the Company’s rapid growth following recent investment New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
More info >>


White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement